Literature DB >> 24725174

Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides.

R N Daggett1, M Kurata, S Abe, I Onishi, K Miura, Y Sawada, T Tanizawa, M Kitagawa.   

Abstract

BACKGROUND: Mycosis fungoides (MF) classically presents from patch stage to plaque stage over a number of years and finally progresses to tumour stage with nodal or visceral involvement. The mechanism of progression remains incompletely elucidated. Chemokines and their receptors are known to be involved in disease mechanisms, with CXCL12 and CXCR4 playing a critical role in carcinogenesis, invasion and cancer cell migration in various carcinomas.
OBJECTIVES: To investigate the expression of CXCL12 and CXCR4 in different cutaneous stages of MF.
METHODS: Formalin-fixed, paraffin-embedded skin samples from 40 patients with MF (21 patch stage, 10 plaque stage, nine tumour stage) and 30 non-neoplastic control skin samples were analysed. CXCL12 and CXCR4 were assessed by quantitative reverse-transcription polymerase chain reaction and immunohistochemical staining.
RESULTS: The expression level of mRNA for CXCL12 in plaque-stage MF was significantly higher than in control skin (P = 0.0035), or patch-stage (P = 0.0108) or tumour-stage disease (P = 0.0089). The CXCR4 mRNA expression level in plaque-stage disease was significantly higher than in control skin (P = 0.0090) or patch-stage disease (P = 0.0387). CXCL12- and CXCR4-positive cell rates in patch-stage and plaque-stage MF were significantly higher than those in control skin (P < 0.0001). CXCL12- and CXCR4-positive cell rates in tumour-stage MF were significantly lower than those in patch- and plaque-stage disease (P = 0.0274 and P = 0.0492, respectively).
CONCLUSIONS: Our data suggest that neoplastic T cells in MF are exposed to the microenvironment, given the abundance of CXCL12 during its progression, and also that neoplastic T cells express CXCR4, especially in the pretumour stage. We reveal that the CXCL12-CXCR4 axis plays a critical role in MF progression.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24725174     DOI: 10.1111/bjd.13054

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.

Authors:  Tzu-Pei Chang; Vladimir Poltoratsky; Ivana Vancurova
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

Review 2.  Recent advances in understanding and managing cutaneous T-cell lymphomas.

Authors:  Patrick M Brunner; Constanze Jonak; Robert Knobler
Journal:  F1000Res       Date:  2020-05-05

3.  Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.

Authors:  Matthias Farlik; Patrick M Brunner; Katharina Rindler; Constanze Jonak; Natalia Alkon; Felix M Thaler; Harald Kurz; Lisa E Shaw; Georg Stingl; Wolfgang Weninger; Florian Halbritter; Wolfgang M Bauer
Journal:  Mol Cancer       Date:  2021-09-28       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.